Hemolysis: Clinical Trials

8 trials for Hemolysis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 8
Phase 21Completed 1

Follow Hemolysis: new trials by email Literature Review of Hemolysis trials Research Report on Hemolysis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
Danicopan, Placebo, C5 Inhibitor - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedAlexion Pharmaceuticals, Inc.862020-12-162025-05-04
Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH
Elizaria®, Soliris® - Paroxysmal Nocturnal Hemoglobinuria, Marchiafava-Micheli Syndrome
Phase 3CompletedAO GENERIUM322017-11-292021-09-01
Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria
Paracetamol - Malaria
Phase 3CompletedMenzies School of Health Research3602016-10-012019-12-19
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
Tafenoquine, Tafenoquine Placebo, Chloroquine - Malaria, Vivax
Phase 3CompletedGlaxoSmithKline2512015-04-302018-05-16
Rituximab in Auto-Immune Hemolytic Anemia
rituximab (Mabthera®), Placebo - Warm Autoimmune Hemolytic Anemia
Phase 3CompletedAssistance Publique - Hôpitaux de Paris322011-03-032017-10-19
Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
Alemtuzumab, Rituximab - Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune
Phase 2 / Phase 3CompletedHospital Universitario Dr. Jose E. Gonzalez192008-08-012010-08-30
L-Arginine and Sickle Cell Disease
L-arginine, Placebo - Sickle Cell Disease
Phase 3CompletedHospital de Clinicas de Porto Alegre402006-09-012010-06-11
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
eculizumab - Paroxysmal Hemoglobinuria, Nocturnal
Phase 3CompletedAlexion Pharmaceuticals, Inc.1872005-05-012018-03-13

Narrower conditions

Anemia (3)  ·  Hemoglobinuria, Paroxysmal (3)  ·  Anemia, Hemolytic (1)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Anemia, Sickle Cell (1)  ·  Bone Marrow Diseases (1)  ·  Hematologic Diseases (1)  ·  Hemoglobinuria (1)  ·  Malaria (1)  ·  Malaria, Vivax (1)  ·  Proteinuria (1)  ·  Pulmonary Arterial Hypertension (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)  ·  Recurrence (1)

Broader conditions

Pathologic Processes (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Hemic and Lymphatic Diseases (6)  ·  Hematologic Diseases (5)  ·  Anemia, Hemolytic (4)  ·  Anemia (3)  ·  Myelodysplastic Syndromes (3)  ·  Bone Marrow Diseases (2)  ·  Infections (2)  ·  Mosquito-Borne Diseases (2)  ·  Parasitic Diseases (2)  ·  Protozoan Infections (2)  ·  Signs and Symptoms (2)  ·  Vector Borne Diseases (2)  ·  Anemia, Hemolytic, Congenital (1)

Interventions

Rituximab (2)  ·  eculizumab (2)  ·  Acetaminophen (1)  ·  Alemtuzumab (1)  ·  Arginine (1)  ·  Chloroquine (1)  ·  Primaquine (1)  ·  danicopan (1)  ·  tafenoquine (1)

Sponsors

Alexion Pharmaceuticals, Inc. (2)  ·  AO GENERIUM (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  GlaxoSmithKline (1)  ·  Hospital Universitario Dr. Jose E. Gonzalez (1)  ·  Hospital de Clinicas de Porto Alegre (1)  ·  Menzies School of Health Research (1)

Countries

Brazil (3)  ·  France (3)  ·  Canada (2)  ·  Germany (2)  ·  Italy (2)  ·  Malaysia (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Thailand (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  Colombia (1)  ·  Czechia (1)

Top investigators

Arjen Dondorp, MD (1)  ·  Bridget Barber, MBBS (1)  ·  Daniel Cooper, MBChB (1)  ·  David Gomez-Almaguer, MD (1)  ·  Giri M Rajahram, MD (1)  ·  Jayaram Menon, MBBS (1)  ·  Katherine Plewes, MD (1)  ·  Matthew Grigg, MBBS (1)  ·  Nicholas Anstey, PhD (1)  ·  Oksana A. Markova, MD (1)  ·  Timothy William, MBBS (1)  ·  Tsin Yeo, MBBS (1)

Results publications

PMID 17702897, PMID 20841509, PMID 29690924, PMID 30650326, PMID 34398258, PMID 35180298, PMID 35732155, PMID 38030318, PMID 39700502

NIH funding

2008 (1), 2019 (1)